Acquiring Company
Eli Lilly and
Acquired Company
AtaiBeckley
Description
Eli Lilly and Co. has completed the acquisition of AtaiBeckley, enhancing its investigational mental health pipeline. The deal includes a cash component and contingent value rights based on future milestones. AtaiBeckley will now operate as a subsidiary, contributing to Lilly's neuroscience initiatives. This acquisition aims to improve options for treatment-resistant depression.
Don't miss Eli Lilly and's next move
Get an email the moment Eli Lilly and makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired AtaiBeckley?
AtaiBeckley was acquired by Eli Lilly and, based in Indianapolis. The deal was reported on September 12, 2026. Eli Lilly and Co. is a leading global pharmaceutical company that develops and delivers innovative pharmaceutical drugs. Eli Lilly and is publicly traded (LLY) and operates in Manufacturing.
When did Eli Lilly and acquire AtaiBeckley?
Eli Lilly and's acquisition of AtaiBeckley was reported on September 12, 2026. Eli Lilly and Co. has completed the acquisition of AtaiBeckley, enhancing its investigational mental health pipeline. The deal includes a cash component and contingent value rights based on future milestones. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AtaiBeckley do?
AtaiBeckley Inc. is a biotechnology company based in Delaware, primarily focused on the development of novel therapeutics for mental health disorders. It is publicly traded (ATAI), operating in Biotechnology, and is based in United States.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.